abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $21.32 and last traded at $20.02, with a volume of 155198 shares. The stock had previously closed at $20.28.
abrdn Life Sciences Investors Stock Down 1.2%
The company has a 50 day simple moving average of $18.19 and a two-hundred day simple moving average of $17.35.
abrdn Life Sciences Investors Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Thursday, May 21st were issued a $0.56 dividend. This represents a $2.24 annualized dividend and a dividend yield of 11.2%. The ex-dividend date of this dividend was Thursday, May 21st.
Hedge Funds Weigh In On abrdn Life Sciences Investors
abrdn Life Sciences Investors Company Profile
abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.
The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.
Featured Stories
- Five stocks we like better than abrdn Life Sciences Investors
- AST SpaceMobile’s Next Launches Could Decide Whether Its Rally Regains Orbit
- 3 Dividend Stocks with Growth on Tap for the Second Half
- 3 Overlooked Stocks Positioned for the Next Market Rotation
- 3 Non-Tech Stocks Still Winning Big on AI
Receive News & Ratings for abrdn Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for abrdn Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.
